Enterprise Evidence Strategy and Partnership
· Partner with therapeutic area EpiRWE Heads, Clinical Development and Global Regulatory Affairs to identify and prioritize opportunities where RWE may accelerate development, strengthen evidence packages, support label expansion, address post-marketing requirements or commitments, or improve the efficiency of evidence generation.
· Provide senior scientific consultation on fit-for-purpose data, study design, endpoint and covariate ascertainment, validation, feasibility and documentation for regulator-facing evidence.
· Facilitate early, cross-functional review of proposed regulatory-facing RWE approaches and provide clear, decision-ready recommendations while preserving program and functional ownership.
· Translate enterprise learning and external precedents into practical decision frameworks that teams can apply across therapeutic areas and lifecycle stages.
Regulatory Science and Health Authority Support
· Partner with Global Regulatory Affairs, who are responsible for agency strategy and relationships, and with program and therapeutic-area teams to shape enterprise strategy for regulatory filing and engagement, as well as develop RWE and methodological content for briefing packages, meeting requests, submissions and responses to health authority questions.
· Support preparation for and, when appropriate, participate in FDA Type B/C meetings, EMA scientific advice and other global health authority interactions in which RWE, external controls, hybrid designs or novel endpoints are material.
· Help coordinate cross-program and cross-region RWE engagement priorities so that scientific positions are consistent, precedents are shared and agency feedback is translated into action.
Study Design and Analytical Innovation
· In partnership with therapeutic area EpiRWE teams, Biostatistics, and Clinical Development teams, advance fit-for-purpose RWE to support regulatory engagement, including external and hybrid controls, target trial emulation, causal inference, natural history studies, phase 0/lead-in studies, pragmatic and registry-based designs, and other innovative approaches.
· Provide regulatory-science perspective on novel analytical methods, including Bayesian borrowing, complex innovative designs, estimands and the documented use of AI/ML or natural language processing in data curation, phenotyping and endpoint derivation.
· Partner with clinical, patient-centered outcomes and other endpoint experts on the selection, validation and regulatory positioning of clinical outcome assessments, digital measures and other novel endpoints.
Policy Shaping and External Partnerships
· Monitor and translate global RWE policy and evidentiary developments into implications for Gilead programs, portfolio strategy and enterprise capabilities.
· Develop and advance policy-shaping priorities related to the regulatory use of RWE, including concepts that could inform future PDUFA demonstration projects, pilots, commitments or other public-private initiatives.
· Coordinate Gilead technical input to draft guidance and consultations, and represent Gilead in relevant consortia, trade associations, professional societies and multi-stakeholder initiatives in alignment with accountable internal functions.
· Identify focused partnerships with academia, professional societies, trade groups, patient advocacy organizations and other stakeholders that can address gaps, test methods, build consensus or advance standards for regulatory-grade RWE.
External Regulatory Centric RWE Ecosystem and Partner Strategy
· Maintain a strategic view of the evolving external environment pertaining to RWE for regulatory use, including data providers, CROs, technology companies, methodological experts, academic centers and specialized service organizations.
· Partner with Sourcing, Legal, Privacy, Quality and functional experts to establish fit-for-purpose evaluation criteria and support due diligence of prospective partners, including scientific credibility, data provenance and quality, regulatory experience, transparency, reproducibility, audit readiness, scalability and potential conflicts of interest.
· Help functions identify credible partners for specific needs, avoid duplicative or low-value engagements, and capture performance and lessons learned to inform future partner selection and investment.
· Provide scientific input to strategic vendor relationships, requests-for-proposal, capability assessments, and external investment decisions without displacing accountable business owners.
Standards, Capability and Matrix Leadership
· Co-develop and steward practical standards, templates, governance and quality expectations for regulatory-facing RWE, aligned with applicable regulations, guidance, Good Pharmacoepidemiology Practices and internal procedures.
· Create forums, training and mentoring programs to strengthen regulatory and methodological judgment across RWE and partner functions and enable teams to apply consistent approaches.
· Deliver concise, executive-level briefings on policy shifts, external developments, precedents, risks and portfolio opportunities.
· Contribute as a member of the EpiRWE leadership team to functional vision, prioritization, ways of working and enterprise initiatives, employee development, and inform resource and investment decisions for enterprise capability, data assets and external partnerships